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Abstracts / Biol Blood Marrow Transplant 21 (2015) S322eS354S332Thus, milatuzumab has potential to inhibit APC-mediated T-
cell proliferation and decrease the risk of aGVHD. In a
xenogeneic SCID mouse model, milatuzumab administered
prior to transplant prevented the development of GVHD,
suppressed circulating cytokines, and reduced the mortality
of the SCID mice (Chen et al, BBMT, 2013).
Methods: We are performing an open-label, single-center
phase 1 dose escalation trial to determine the maximum
tolerated dose (MTD) of milatuzumab when added to stan-
dard GVHD prophylaxis using reduced-intensity condition-
ing (RIC) for HLA matched (8/8) sibling or unrelated SCT.
Patients (pts) are premedicated with dexamethasone and
receive milatuzumab intravenously on days -7, -4, -1, and +7.
The initial starting dose was 8 mg/kg (DL1) with dose esca-
lation to 16 mg/kg (DL2) and 20 mg/kg in cohorts of 3-6 until
unacceptable toxicity. Dose limiting toxicities are deﬁned as
graft failure, any  grade 4 organ toxicities excluding ex-
pected hematologic toxicities from SCT, or grade 4 infusion
reactions attributable to milatuzumab. Acute and chronic
GVHDwas recorded according to Consensus and NIH criteria,
respectively.
Results: Nine pts have been treated with median follow up
of 56 days post transplant (average 121 days; range 13-
294). The median age is 57 years (range 26-70). Pts had a
variety of hematologic malignancies. Median Sorror co-
morbidity score was 1 (range 0-8). Recipients received RIC
with ﬂudarabine (30 mg/m2days -7 through -3) and
busulfan (0.8 mg/kg every 6 hours days -4 and -3 for total
of 8 doses) along with tacrolimus and methotrexate (D+ 1,
3, 6, & 11). Donors were 8/8 HLA-matched siblings or
matched unrelated. All pts received four doses of milatu-
zumab and 3 or 4 doses of methotrexate. Three individuals
were initially treated at DL1 followed by 3 pts at DL2. At
DL2, one pt died from relapsed AML, and 2 pts died from
grade 5 sepsis. At DL2, only one experienced GVHD (grade
4 cutaneous that was indistinguishable from Stevens-
Johnson Syndrome). As a result, three more pts were
enrolled to DL1 to assess safety. Only 1 of 6 pts at DL1 had
toxicity attributable to milatuzumab (grade 1 tremor). InFigure 1. Phosphoﬂow assaDL1, 3 of 6 had aGVHD with 2 of 3 experiencing grade 1 and
one grade 2 cutaneous GVH.
Conclusions: While the grade 5 events in DL2 (16 mg/kg)
were not considered speciﬁcally attributable to milatuzu-
mab, DL1 (8mg/kg) has been well tolerated without any
grade 3 GVHD. We will continue to monitor at DL1 and
pending tolerability may amend the protocol to test an in-
termediate dose of 12 mg/kg. Milatuzumab remains an
intriguing potential agent to prevent aGVHD.483
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Background: Brief CCR5blockadeusingmaraviroc (MVC) after
reduced-intensity alloSCT resulted in a low incidence of acute
GvHD and protection against visceral GvHD. We observed sig-
niﬁcant variability in baseline T-cell CCR5 expression in donors
and recipients. We therefore hypothesized that effective
blockade of CCR5 activation is dependent on its baseline
expression. To test this,wedeveloped aphosphoﬂowassay that
measures the activity of MVC in fresh blood samples.
Methods: The phosphoﬂow assay (Fig. 1) quantiﬁes CCR5
activationbymeasuringphosphorylationof a C-terminal serine
residue (SER349) using a phosphospeciﬁc CCR5 antibody. To
demonstrate activity, CCL4 stimulationwas performed in fresh
whole blood with or without excess MVC. Change in pCCR5
levels was measured as the MFI fold-change from a baseliney for CCR5 activation
Figure 2. Fold-change in pCCR5 on CD8 T-cells in response to CCL4 stimula-
tion with or without MVC
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measured separately by ﬂow cytometry.
Results: Twenty-four reduced-intensity alloSCT recipients
received MVC 300 mg b.i.d. orally from day -3 to day +90 on
an ongoing phase II study. Recipient bloodwas tested on days
-6 (beforeMVC), 0 and 14, and donor bloodwas tested on day
0. We observed signiﬁcant variability in surface CCR5
expression on T-cells in donors (range 0e9%) and recipients
(range 0e49%). Recipient surface CCR5 expression increased
from d-6 to d0 on both CD4 (mean 3.6 to 7.3%, p¼0.005) and
CD8 (mean 13.5 to 30.6%, p¼0.005) T-cells, consistent with
blockade of receptor internalization.
CD8 T-cell pCCR5 levels increased in response to CCL4
stimulation on d -6 (p¼0.01) and decreased in response to
MVC (p¼0.002), compared to unstimulated blood (Fig. 2). A
decrease in pCCR5 levels in response to MVC was observed
evenwithout CCL4 stimulation, reﬂecting loss of background
CCR5 activity (p¼0.0002). In contrast, d0 pCCR5 levels failed
to increase in response to CCL4 (p¼0.32), nor did they
decrease in response to additional MVC (p¼0.13), mirroring
effective in vivo blockade of CCR5.
The magnitude of increase in CD8 T-cell pCCR5 levels in
response to CCL4 stimulation on d-6 correlated with CCR5
surface expression (r¼0.55, p¼0.02). The same was true of
CD4 T-cells (r¼0.76, p¼0.0004). On d0, however, the ability
to stimulate CCR5 inversely correlated with CCR5
surface expression for both CD8 (r¼-0.46, p¼0.04) and CD4
(r¼-0.62, p¼0.004), suggesting that greater CCR5 surface
upregulation may serve as an indicator for complete re-
ceptor blockade.
Conclusions: Intracellular phosphorylation of CCR5 in
response to stimulation is efﬁciently blocked by MVC in pa-
tients undergoing alloSCT, as measured by a novel phos-
phoﬂow assay. Upregulation of surface CCR5 may indicate
effective CCR5 blockade and should be explored as a
biomarker for drug response.484
CD4+CD25+ Invariant Natural Killer T Cells Are Enriched
in Cord Blood: Implication on Immune-Regulation
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Cellular Therapy, The University of Texas MD Anderson Cancer
Center, Houston, TXCD1d-restricted invariant Natural Killer (iNK) T cells are rare
but powerful regulatory T cells that can produce a large
amount of both inﬂammatory (Th-1 type) and regulatory
(Th-2 type) cytokines upon activation. Therefore, they can
potentially shape subsequent adaptive immune responses
towards inﬂammation or immune tolerance. Unlike the other
regulatory immune cells, iNK T cells are heterogeneous in
phenotype (CD4+ vs CD4- vs CD8a+), and display a spectrum
of function ranging from regulatory to inﬂammatory re-
sponses. Given the potential regulatory function, iNKT cells
are thought to play a role in preventing Graft Versus Host
Disease (GVHD) in allogeneic stem cell transplant (SCT). Yet,
the precisemechanism of immune regulation by iNKTcells in
allogeneic SCT setting has not been clearly elucidated. As the
cord blood stem cell transplantation is known to have a
reduced incidence of GVHD as compared to matched adult
donor allogeneic SCT, we hypothesize that iNK T cells in cord
blood possess the regulatory phenotype and function as
compared to those in healthy adults, thus play a role in
preventing GVHD. To test this hypothesis, we ﬁrst charac-
terized the phenotype of iNK T cells from 25 cord blood and
25 peripheral blood of healthy adults using multi-color Flow
Cytometry.We found that iNK Tcells were present in variable
frequencies ranging from 0.01% to 2% of T cells from healthy
adults but rather in similar frequencies around 0.1% of T cells
from cord blood. Interestingly, the extremely high percent-
age of CD4+CD25+CD161- iNK T cells was present in cord
blood, while iNK T cells from healthy adults were heteroge-
neous in phenotype with a trend towards higher percentage
of CD4-CD25-CD161+ iNK T cells. Next, we investigated
whether CD4+CD25+ iNK T cells from cord blood indeed
display regulatory property, and assessed cytokine produc-
tion proﬁle of ex vivo expanded polyclonal iNK T cells stim-
ulated by autologous or allogeneic dendritic cells in the
presence of alpha-GalCer, agonist glycolipid antigen. We
found that the iNK T cells from cord blood preferentially
produced Th-2 type cytokines (GM-CSF, IL-13, IL-4, IL-5) as
compared to iNK T cells from healthy adults. Lastly, poly-
clonal iNK T cells showed signiﬁcant cytokine production to
autologous or allogeneic dendritic cells in the absence of
alpha-GalCer, suggesting that iNK T cells can be activated by
endogenous glycolipid antigens in physiologic condition. In
summary, we demonstrated that CD4+CD25+CD161-iNK T
cells were enriched in cord blood, and indeed displayed
regulatory property. Our results sugest that CD4+CD25+ iNK
T cells may play role in immunoregulation to prevent GVHD
via regulatory function.485
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Background and Objective: Antineoplastic MEK inhibitors
have immunomodulatory activity. MEK inhibition selectively
suppresses naïve/central memory T cells while sparing
effector memory T cells, and delays the onset of murine
GVHD (Shindo, Kim, Komanduri et al. Blood 2013). We
investigated whether MEK inhibition selectively suppresses
